Biodexa Net Income From Continuing Ops from 2010 to 2024
| BDRX Stock | 5.62 0.69 14.00% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -7.1 M | Current Value -7.4 M | Quarterly Volatility 3.7 M |
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.9 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.34. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
Biodexa | Net Income From Continuing Ops |
Latest Biodexa Pharmaceticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Biodexa Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (9,413,130) | |
| Coefficient Of Variation | (39.35) | |
| Mean Deviation | 1,703,449 | |
| Median | (9,138,000) | |
| Standard Deviation | 3,703,896 | |
| Sample Variance | 13.7T | |
| Range | 16.7M | |
| R-Value | 0.03 | |
| Mean Square Error | 14.8T | |
| R-Squared | 0.001 | |
| Significance | 0.91 | |
| Slope | 25,923 | |
| Total Sum of Squares | 192.1T |
Biodexa Net Income From Continuing Ops History
About Biodexa Pharmaceticals Financial Statements
Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.1 M | -7.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.